Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 4-39 (IGHV4-39)
- Target
- IGHV4-39
- Molecular classification
- Other (immunoglobulin variable gene segment), Component of the antibody heavy chain variable region
01
Overview
Immunoglobulin heavy variable 4-39 (IGHV4-39) is a gene segment within the human immunoglobulin heavy chain locus on chromosome 14, encoding the variable region of the antibody heavy chain. This variable region enables a diverse repertoire of antigen binding for humoral immune responses. IGHV genes contribute to the adaptive immune system by generating diversity through V(D)J recombination and somatic hypermutation. IGHV4-39 variants and usage frequency can affect antibody responses and have been studied in association with autoimmunity, infectious diseases, and B-cell malignancies. However, IGHV4-39 is not considered a druggable target, but rather a crucial genomic element in immunology and disease.
- Other names
- IGHV4-39Ig heavy chain V-II region WAHIGHV439VHimmunoglobulin heavy chain variable region
02
Biological functions
Antigen bindingAdaptive immune responseHumoral immunity (contributes to antibody function)
03
Disease associations
Cancer (clonal expansions/mutations in IGHV genes may be relevant in B-cell lymphomas and leukemias; IGHV4-39 usage is studied in disease contexts, but not directly a target)Other (autoimmune disorders and infectious disease influence antibody repertoires)
04
Safety considerations
None specific (No noted safety concerns or therapeutic challenges; rather, somatic mutation or aberrant IGHV segment usage may be relevant in B-cell disorders)
05
Biomarkers
IGHV4-39 gene usage may be a biomarker in clinical studies assessing immunoglobulin repertoire diversity or aberrant clonal expansion (such as in certain B-cell malignancies)IGHV gene usage may serve as biomarker in disease stratification, but IGHV4-39 is not uniquely used for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Immunoglobulin heavy variable 4-39 (IGHV4-39).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin heavy variable 4-39 (IGHV4-39).